 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Adavosertib combined with various chemotherapy drugs in the treatment of primary platinum-resistant ovarian, fallopian tube, and peritoneal cancers

Clin Cancer Res: Adavosertib combined with various chemotherapy drugs in the treatment of primary platinum-resistant ovarian, fallopian tube, and peritoneal cancers

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

alumina tube

boc study guide

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Adavosertib (AZD1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antitumor activity
.

The aim of this study was to evaluate the efficacy, safety and pharmacokinetics of Adavosertib combined with four commonly used chemotherapeutic agents for primary platinum-resistant ovarian

This is an open-label, four-arm, multicenter Phase II clinical trial that enrolled 94 histologically or cytologically confirmed epithelial tumors with measurable lesions between January 2015 and January 2018.
Patients with ovarian, fallopian tube, or peritoneal cancer
.

Patients were divided into 6 cohorts and received 175 mg-225 mg of Adavosertib (oral capsule, 2 days on, 5 days off, or 3 days on, 4 days off) in combination with gemcitabine, paclitaxel, carboplatin, or pegylated daily Liposomal doxorubicin

Remission in each treatment group

Of the 94 patients, 3 (3%) achieved a verified complete response and 27 (29%) achieved an objective response
.

The cohort with the highest response rate was the carboplatin plus Adavosertib group , with a response rate and disease control rate of 66.

Of the 94 patients, 3 (3%) achieved a verified complete response and 27 (29%) achieved an objective response

Most common side effects

In conclusion, adavosertib demonstrated initial therapeutic activity in combination with chemotherapeutic agents in the study patient population
.

The most promising treatment combination is Adavosertib 225 mg twice daily plus carboplatin every 21 days on days 1-3, 8-10, and 15-17

Adavosertib exhibits initial therapeutic activity in combination with chemotherapeutic agents in the study patient population Adavosertib exhibits initial therapeutic activity in combination with chemotherapeutic agents in the study patient population

Original source:

Kathleen N.

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II StudyLeave a Comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.